Saturday 17 October 2026
Export PGNY’s income statement to Excel — free account
Progyny, Inc.
PGNY Healthcare Healthcare Plans
Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 5.30%, EPS grew 80.0% and free cash flow fell 12.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
26.86
0.60
−2.18%
Follow PGNY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
29.72 | 20.96 | 37.22 | 32.61 |
+8 more quarters Free account |
P/S ratio |
1.72 | 1.06 | 1.71 | 1.46 | |
P/FCF ratio |
12.63 | 7.45 | 11.47 | 9.57 | |
P/Operating CF |
44.69 | 29.90 | 40.58 | 36.53 | |
P/B ratio |
4.97 | 3.13 | 4.26 | 3.31 | |
Price to Tangible BV |
5.27 | 3.32 | 4.49 | 3.47 | |
EV/Sales |
1.54 | 0.89 | 1.47 | 1.19 | |
EV/EBITDA |
17.15 | 11.33 | 20.99 | 16.14 | |
EV/Operating CF |
10.04 | 5.59 | 9.01 | 7.26 | |
EV/FCF |
11.33 | 6.26 | 9.88 | 7.81 | |
Quick Ratio |
2.06 | 2.07 | 2.62 | 2.84 | |
Current Ratio |
2.14 | 2.13 | 2.73 | 2.96 | |
Net Debt/EBITDA |
(5.69) | (6.11) | (18.22) | (15.44) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.78 | 1.81 | 1.91 | 1.74 | |
Operating CF/Net income |
1.80 | 1.90 | 4.34 | 3.65 | |
Capex/Depreciation |
(3.83) | (4.28) | (3.12) | (5.60) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
14.06% | 14.52% | 19.37% | 16.37% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.04 | 0.03 | |
Share Based Compensation of Revenue |
5.84% | 6.00% | 10.93% | 10.27% | |
Graham Net Nets |
0.11 | 0.18 | 0.15 | 0.21 | |
Graham Number |
11.25 | 9.95 | 9.67 | 9.83 | |
Earnings Yield |
3.36% | 4.77% | 2.69% | 3.07% | |
Free Cash Flow Yield |
7.92% | 13.42% | 8.72% | 10.45% | |
Revenue per Share |
4.48 | 4.06 | 3.72 | 3.64 | |
Operating CF per Share |
0.65 | 0.57 | 0.63 | 0.59 | |
Capex per Share |
(0.08) | (0.08) | (0.07) | (0.05) | |
Free Cash Flow per Share |
0.57 | 0.49 | 0.57 | 0.53 | |
Cash per Share |
3.03 | 2.78 | 3.62 | 4.01 | |
Shareholders Equity per Share |
5.80 | 5.43 | 6.02 | 6.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.80 | 5.43 | 6.02 | 6.51 | |
Free Cash Flow |
44.21 | 39.60 | 48.59 | 45.99 | |
Working Capital |
272.93 | 265.81 | 349.38 | 411.52 | |
Capital Expenditures |
(6.22) | (6.35) | (5.61) | (4.68) | |
Net Current Asset Value |
250.44 | 242.56 | 325.38 | 386.79 | |
EV/EBIT |
18.03 | 11.96 | 22.21 | 17.60 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.01 | |
Price to Operating Income |
20.10 | 14.24 | 25.79 | 21.56 | |
| Other line items | |||||
Average Receivables |
264.66 | 281.68 | 227.81 | 266.61 | |
Average Payables |
146.28 | 151.77 | 109.58 | 126.78 | |
Average Assets |
738.39 | 714.31 | 674.77 | 727.60 | |
Average Common Equity |
484.14 | 453.25 | 469.05 | 497.44 |
Columns are period end dates